Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients

Research output: Contribution to journalArticle

38 Citations (Scopus)

Abstract

Cytomegalovirus is the most common viral pathogen that affects solid organ transplant recipients. It directly causes fever, myelosuppression, and tissue-invasive disease, and indirectly, it negatively impacts allograft and patient survival. Nucleic acid amplification testing is the preferred method to confirm the diagnosis of CMV infection. Prevention of CMV disease using antiviral prophylaxis or preemptive therapy is critical in the management of transplant patients. Intravenous ganciclovir and oral valganciclovir are the first line drugs for antiviral treatment. This article provides a comprehensive review of the current epidemiology, diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients.

Original languageEnglish (US)
Pages (from-to)317-342
Number of pages26
JournalInfectious Disease Clinics of North America
Volume27
Issue number2
DOIs
StatePublished - Jun 2013

Fingerprint

Cytomegalovirus Infections
Transplants
Antiviral Agents
Ganciclovir
Infection
Cytomegalovirus
Nucleic Acids
Allografts
Epidemiology
Fever
Therapeutics
Survival
Transplant Recipients

Keywords

  • Allograft rejection
  • Cytomegalovirus
  • Graft failure
  • Nucleic acid testing
  • Polymerase chain reaction
  • Valganciclovir
  • Viral load

ASJC Scopus subject areas

  • Microbiology (medical)
  • Infectious Diseases

Cite this

@article{7410f39f2dc34fb18880b1c331b20e51,
title = "Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients",
abstract = "Cytomegalovirus is the most common viral pathogen that affects solid organ transplant recipients. It directly causes fever, myelosuppression, and tissue-invasive disease, and indirectly, it negatively impacts allograft and patient survival. Nucleic acid amplification testing is the preferred method to confirm the diagnosis of CMV infection. Prevention of CMV disease using antiviral prophylaxis or preemptive therapy is critical in the management of transplant patients. Intravenous ganciclovir and oral valganciclovir are the first line drugs for antiviral treatment. This article provides a comprehensive review of the current epidemiology, diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients.",
keywords = "Allograft rejection, Cytomegalovirus, Graft failure, Nucleic acid testing, Polymerase chain reaction, Valganciclovir, Viral load",
author = "Razonable, {Raymund R}",
year = "2013",
month = "6",
doi = "10.1016/j.idc.2013.02.005",
language = "English (US)",
volume = "27",
pages = "317--342",
journal = "Infectious Disease Clinics of North America",
issn = "0891-5520",
publisher = "W.B. Saunders Ltd",
number = "2",

}

TY - JOUR

T1 - Management strategies for cytomegalovirus infection and disease in solid organ transplant recipients

AU - Razonable, Raymund R

PY - 2013/6

Y1 - 2013/6

N2 - Cytomegalovirus is the most common viral pathogen that affects solid organ transplant recipients. It directly causes fever, myelosuppression, and tissue-invasive disease, and indirectly, it negatively impacts allograft and patient survival. Nucleic acid amplification testing is the preferred method to confirm the diagnosis of CMV infection. Prevention of CMV disease using antiviral prophylaxis or preemptive therapy is critical in the management of transplant patients. Intravenous ganciclovir and oral valganciclovir are the first line drugs for antiviral treatment. This article provides a comprehensive review of the current epidemiology, diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients.

AB - Cytomegalovirus is the most common viral pathogen that affects solid organ transplant recipients. It directly causes fever, myelosuppression, and tissue-invasive disease, and indirectly, it negatively impacts allograft and patient survival. Nucleic acid amplification testing is the preferred method to confirm the diagnosis of CMV infection. Prevention of CMV disease using antiviral prophylaxis or preemptive therapy is critical in the management of transplant patients. Intravenous ganciclovir and oral valganciclovir are the first line drugs for antiviral treatment. This article provides a comprehensive review of the current epidemiology, diagnosis, prevention and treatment of CMV infection in solid organ transplant recipients.

KW - Allograft rejection

KW - Cytomegalovirus

KW - Graft failure

KW - Nucleic acid testing

KW - Polymerase chain reaction

KW - Valganciclovir

KW - Viral load

UR - http://www.scopus.com/inward/record.url?scp=84878231546&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84878231546&partnerID=8YFLogxK

U2 - 10.1016/j.idc.2013.02.005

DO - 10.1016/j.idc.2013.02.005

M3 - Article

VL - 27

SP - 317

EP - 342

JO - Infectious Disease Clinics of North America

JF - Infectious Disease Clinics of North America

SN - 0891-5520

IS - 2

ER -